| Attribute |
Value |
| 52 Week Change |
-0.28695655 |
| Address1 |
1,111 Lincoln Road |
| Address2 |
Suite 500 |
| All Time High |
170.0 |
| All Time Low |
0.281 |
| Ask |
0.5937 |
| Ask Size |
2 |
| Average Analyst Rating |
1.0 - Strong Buy |
| Average Daily Volume10 Day |
2,975,630 |
| Average Daily Volume3 Month |
838,932 |
| Average Volume |
838,932 |
| Average Volume10Days |
2,975,630 |
| Beta |
0.287 |
| Bid |
0.3371 |
| Bid Size |
2 |
| Book Value |
2.198 |
| City |
Miami Beach |
| Compensation As Of Epoch Date |
1,767,139,200 |
| Country |
United States |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
0.49 |
| Current Ratio |
35.402 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,782,777,600 |
| Day High |
0.4996 |
| Day Low |
0.45 |
| Display Name |
Pasithea Therapeutics |
| Earnings Timestamp End |
1,755,374,400 |
| Earnings Timestamp Start |
1,754,942,400 |
| Ebitda |
-17,232,384 |
| Ebitda Margins |
0.0 |
| Enterprise To Ebitda |
1.975 |
| Enterprise Value |
-34,027,296 |
| Eps Current Year |
-0.76 |
| Eps Forward |
-1.01 |
| Eps Trailing Twelve Months |
-1.42 |
| Esg Populated |
0 |
| Exchange |
NCM |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
0.64792 |
| Fifty Day Average Change |
-0.15792 |
| Fifty Day Average Change Percent |
-0.2437338 |
| Fifty Two Week Change Percent |
-28.695656 |
| Fifty Two Week High |
2.06 |
| Fifty Two Week High Change |
-1.5699999 |
| Fifty Two Week High Change Percent |
-0.7621359 |
| Fifty Two Week Low |
0.281 |
| Fifty Two Week Low Change |
0.20900002 |
| Fifty Two Week Low Change Percent |
0.7437723 |
| Fifty Two Week Range |
0.281 - 2.06 |
| Financial Currency |
USD |
| First Trade Date Milliseconds |
1,631,712,600,000 |
| Float Shares |
16,624,022 |
| Forward Eps |
-1.01 |
| Forward P E |
-0.48514852 |
| Free Cashflow |
-11,838,196 |
| Full Exchange Name |
NasdaqCM |
| Full Time Employees |
5 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.0 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.01114 |
| Held Percent Institutions |
0.70341 |
| Implied Shares Outstanding |
33,414,448 |
| Industry |
Biotechnology |
| Industry Disp |
Biotechnology |
| Industry Key |
biotechnology |
| Ipo Expected Date |
2,021-09-15 |
| Is Earnings Date Estimate |
1 |
| Language |
en-US |
| Last Fiscal Year End |
1,767,139,200 |
| Last Split Date |
1,704,153,600 |
| Last Split Factor |
1:20 |
| Long Business Summary |
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. |
| Long Name |
Pasithea Therapeutics Corp. |
| Market |
us_market |
| Market Cap |
16,373,080 |
| Market State |
PRE |
| Max Age |
86,400 |
| Message Board Id |
finmb_702706441 |
| Most Recent Quarter |
1,774,915,200 |
| Net Income To Common |
-19,733,928 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
16,453,274 |
| Number Of Analyst Opinions |
1 |
| Open |
0.5054 |
| Operating Cashflow |
-16,942,952 |
| Operating Margins |
0.0 |
| Payout Ratio |
0.0 |
| Phone |
786 977 3380 |
| Pre Market Change |
0.0 |
| Pre Market Change Percent |
0.0 |
| Pre Market Price |
0.49 |
| Pre Market Time |
1,784,016,018 |
| Previous Close |
0.4924 |
| Price Eps Current Year |
-0.6447369 |
| Price Hint |
4 |
| Price To Book |
0.22292994 |
| Profit Margins |
0.0 |
| Quick Ratio |
33.837 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
strong_buy |
| Recommendation Mean |
1.0 |
| Region |
US |
| Regular Market Change |
-0.00239998 |
| Regular Market Change Percent |
-0.487405 |
| Regular Market Day High |
0.4996 |
| Regular Market Day Low |
0.45 |
| Regular Market Day Range |
0.45 - 0.4996 |
| Regular Market Open |
0.5054 |
| Regular Market Previous Close |
0.4924 |
| Regular Market Price |
0.49 |
| Regular Market Time |
1,783,972,801 |
| Regular Market Volume |
403,016 |
| Return On Assets |
-0.31491 |
| Return On Equity |
-0.5822 |
| Sand P52 Week Change |
0.20847368 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
33,414,448 |
| Shares Percent Shares Out |
0.0086 |
| Shares Short |
287,315 |
| Shares Short Previous Month Date |
1,780,012,800 |
| Shares Short Prior Month |
274,584 |
| Short Name |
Pasithea Therapeutics Corp. |
| Short Percent Of Float |
0.0087 |
| Short Ratio |
0.18 |
| Source Interval |
15 |
| State |
FL |
| Symbol |
KTTA |
| Target High Price |
3.0 |
| Target Low Price |
3.0 |
| Target Mean Price |
3.0 |
| Target Median Price |
3.0 |
| Total Cash |
50,400,376 |
| Total Cash Per Share |
1.508 |
| Total Debt |
0 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
0.0 |
| Trailing Annual Dividend Yield |
0.0 |
| Trailing Eps |
-1.42 |
| Trailing Peg Ratio |
None |
| Triggerable |
1 |
| Two Hundred Day Average |
0.789555 |
| Two Hundred Day Average Change |
-0.299555 |
| Two Hundred Day Average Change Percent |
-0.37939724 |
| Type Disp |
Equity |
| Volume |
403,016 |
| Website |
https://www.pasithea.com |
| Zip |
33,139 |